You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 11, 2025

Details for Patent: 9,687,506


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,687,506
Title:Sodium nitrite-containing pharmaceutical compositions
Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
Inventor(s): Sherman; Craig (Scottsdale, AZ), Lepine; Anthony James (Greendale, WI), Smith; Catherine Marie (Grafton, WI), Wirtz; Kevin Robert (Belgium, WI), Schulze; Erich (Mission Viejo, CA)
Assignee: Hope Medical Enterprises, Inc. (Scottsdale, AZ)
Application Number:15/251,015
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Device; Dosage form;
Patent landscape, scope, and claims:

United States Patent 9,687,506: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 9,687,506, titled "Sodium nitrite-containing pharmaceutical compositions," is a significant patent in the pharmaceutical sector, particularly in the area of emergency medical treatments. This patent is associated with the drug Nithiodote, which is used for treating cyanide poisoning and other conditions. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Inventors and Assignees

The patent was granted to inventors associated with Hope Pharmaceuticals, the company that markets Nithiodote. Understanding the inventors and assignees is crucial as it highlights the ownership and control over the intellectual property.

Publication and Grant Dates

The patent was published and granted on various dates, with the most recent activities indicating ongoing maintenance and updates. For instance, recent records show patent grant notifications and maintenance fee payments, ensuring the patent remains active[5].

Scope of the Patent

Pharmaceutical Compositions

The patent focuses on pharmaceutical compositions containing sodium nitrite, often used in conjunction with sodium thiosulfate. These compositions are critical for reducing the risk of hospital-acquired infections and treating conditions such as cyanide poisoning[4].

Therapeutic Uses

The scope extends to various therapeutic uses, including the treatment of cyanide poisoning, which is a life-threatening condition. The patent also touches on the prevention of nosocomial infections, highlighting its broad applicability in medical emergencies[4].

Claims of the Patent

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the composition, method of preparation, and specific uses of the sodium nitrite-containing pharmaceuticals. For example, Claim 1 might describe a pharmaceutical composition comprising a specific concentration of sodium nitrite and sodium thiosulfate[4].

Dependent Claims

Dependent claims further specify the invention by adding additional limitations or features to the independent claims. These could include specific dosages, administration methods, or additional ingredients that enhance the efficacy or stability of the composition.

Patent Landscape

Patent Family and International Protection

The patent is part of a larger patent family with protections in multiple countries. For Nithiodote, there are fifty-six patent family members in fifteen countries, indicating a robust global intellectual property strategy[1].

US Patents and Regulatory Protections

In the United States, Nithiodote is protected by seven patents, with the earliest generic entry date estimated to be December 24, 2031, subject to patent challenges or licensing agreements[1][5].

Patent Litigation and Challenges

There have been patent litigation cases involving the patents protecting Nithiodote, reflecting strong interest in generic versions. Recent data suggest that a significant percentage of patent challenges are decided in favor of generic challengers, who often promptly launch generic drugs following a successful challenge[1].

Nonobviousness and Novelty Requirements

Nonobviousness

The patent must meet the nonobviousness requirement, meaning the invention must be significantly different from existing knowledge in the field. The Patent Trial and Appeal Board (PTAB) and judicial reviews ensure that the claimed invention is not obvious to a person of ordinary skill in the art[3].

Novelty

The novelty requirement ensures that the claimed invention is new and not previously disclosed in the prior art. This is a fundamental requirement for patentability, and any failure to meet this criterion can result in the patent being invalidated[3].

Eligible Subject Matter

The patent claims must be directed to eligible subject matter, excluding laws of nature, natural phenomena, and abstract ideas. The Alice/Mayo test is often applied to determine if the patent claims have an "inventive concept" that transforms the nature of the claim into a patent-eligible application[3].

Impact on the Pharmaceutical Industry

Market Position and Competition

The unique market position of Nithiodote, coupled with its critical therapeutic uses, makes it a significant player in the pharmaceutical industry. The patent protections ensure that Hope Pharmaceuticals maintains market exclusivity, influencing the financial trajectory of the drug[1].

Generic Entry and Competition

The estimated generic entry date and potential challenges to the patent can significantly impact the market dynamics. Generic entry can lead to increased competition, potentially reducing the market share and revenue of the branded drug[1].

Conclusion

The United States Patent 9,687,506 is a critical intellectual property asset for Hope Pharmaceuticals, protecting the drug Nithiodote. The scope of the patent encompasses specific pharmaceutical compositions and therapeutic uses, with a robust patent landscape that includes international protections and ongoing litigation.

Key Takeaways

  • Patent Scope: The patent covers sodium nitrite-containing pharmaceutical compositions, particularly for treating cyanide poisoning and preventing nosocomial infections.
  • Claims: Independent and dependent claims define the invention, including composition, preparation, and specific uses.
  • Patent Landscape: Protected by seven US patents and fifty-six international patent family members, with an estimated generic entry date of December 24, 2031.
  • Regulatory Protections: Meets nonobviousness, novelty, and eligible subject matter requirements.
  • Market Impact: Significant market exclusivity for Hope Pharmaceuticals, with potential competition from generic entries.

FAQs

1. What is the primary use of the drug protected by United States Patent 9,687,506?

The primary use of the drug protected by this patent is the treatment of cyanide poisoning and the prevention of nosocomial infections.

2. How many US patents protect Nithiodote?

Nithiodote is protected by seven US patents.

3. What is the estimated generic entry date for Nithiodote?

The estimated generic entry date for Nithiodote is December 24, 2031, subject to patent challenges or licensing agreements.

4. What are the key components of the pharmaceutical composition described in the patent?

The key components are sodium nitrite and sodium thiosulfate.

5. Why is the patent landscape important for Nithiodote?

The patent landscape is crucial as it ensures market exclusivity for Hope Pharmaceuticals, influencing the financial trajectory and competitive position of the drug.

Cited Sources:

  1. Drug Patent Watch - Nithiodote Drug Patent Profile
  2. CAFC - INTEL CORPORATION v. PACT XPP SCHWEIZ AG
  3. Congressional Research Service - The Patent Trial and Appeal Board and Inter Partes Review
  4. Google Patents - Sodium nitrite-containing pharmaceutical compositions
  5. Pharsight - Nithiodote patent expiration

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,687,506

Showing 1 to 4 of 4 entries

International Family Members for US Patent 9,687,506

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2010213743 ⤷  Subscribe
Canada 2752129 ⤷  Subscribe
Cyprus 1124426 ⤷  Subscribe
Denmark 2395834 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.